IRVINE, Calif., June 17, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Amyris, Inc. ("Amyris" or the "Company") AMRS. Investors who purchased or otherwise acquired shares between March 2, 2017 and April 17, 2017 inclusive (the "Class Period"), are encouraged to contact the Firm by the June 19, 2017 lead plaintiff motion deadline.
If you purchased Amyris shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Amyris made false and/or misleading statements and/or failed to disclose: that in the first quarter of 2017, the Company made a decision to take an equity stake in one of Blue California's affiliates that focused on the sweetener market instead of cash payment under the license agreement; that due to this decision Amyris would be unable to recognize $10 million in fourth quarter and fiscal year 2016 revenue from the license agreement with Blue California; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. When this news reached the public, Amyris' share price dropped materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esquire, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 joon@khanglaw.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.